TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10704632

Group type: EXPERIMENTAL
Intervention: Atorvastatin (initial dose 10 mg, max 80 mg)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Simvastatin (initial dose 10 mg, max 40 mg, supplemented with 4 g cholestyramine if necessary)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Simvastatin (10 mg)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Atorvastatin (for baseline cholesterol 5.6-6.5 mmol/l)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Simvastatin (for baseline cholesterol 5.6-6.5 mmol/l)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Atorvastatin (for baseline cholesterol 7.6-8.5 mmol/l)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Simvastatin (for baseline cholesterol 7.6-8.5 mmol/l)
Number of subjects: 1028
Study: 9346224

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) with carboplatin (AUC 7)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m2) with carboplatin (AUC 7) alternating with cisplatin (75 mg/m2)
Number of subjects: 90
Study: 7971879

Group type: EXPERIMENTAL
Intervention: Self-help manual smoking cessation intervention
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 265
Study: 2637911

Group type: EXPERIMENTAL
Intervention: PT-01 (controlled-release insert containing ofloxacin)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PT-01
Number of subjects: 46
Study: 974477

Group type: EXPERIMENTAL
Intervention: Surgical transposition of the ovaries
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no ovaria transposition)
Number of subjects: 10
Study: 31300065

Group type: EXPERIMENTAL
Intervention: Online Cutting Down Programme (CDP)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Online Psychoeducation
Number of subjects: 700
Study: 28061037

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic surgery (SPLS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 62
Study: 25423960

Group type: EXPERIMENTAL
Intervention: S-1 adjuvant chemotherapy (S-1(+)-group) administered after 2003
Number of subjects: 38

Group type: COMPARATOR
Intervention: No S-1 adjuvant chemotherapy (S-1(-)-group) before 2003
Number of subjects: 38
Study: 23530078

Group type: EXPERIMENTAL
Intervention: Combination artesunate (AS)/amodiaquine (AQ) therapy
Number of subjects: 109
Study: 21791541

Group type: EXPERIMENTAL
Intervention: Low homoarginine levels
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Lowest homoarginine quintile
Number of subjects: 1255
Study: 18751881

Group type: EXPERIMENTAL
Intervention: Stimuli of different salience presented to participants with ASD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Over-selected color extinguished in Experiment 3
Number of subjects: 0
Study: 16458644

Group type: EXPERIMENTAL
Intervention: Sulprostone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 15499517

Group type: EXPERIMENTAL
Intervention: Liposome eye spray (TEARS AGAIN, Optima Pharmaceutical GmbH, Germany)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Liposome eye spray (TEARS AGAIN)
Number of subjects: 382
Study: 11755562

Group type: EXPERIMENTAL
Intervention: Atenolol therapy for high cardiac output (greater than 7.4 L/minute)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (low risk, not treated)
Number of subjects: 46
Study: 8950737

Group type: EXPERIMENTAL
Intervention: Erythromycin (E)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 57
Study: 1720486

Group type: EXPERIMENTAL
Intervention: isradipine 1.25-2.5 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: metoprolol 50-100 mg twice daily
Number of subjects: 12
Study: 6817845

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate treatment for 6 months
Number of subjects: 179

Group type: COMPARATOR
Intervention: Vitamin C treatment for 6 months
Number of subjects: 179
Study: 29962032

Group type: EXPERIMENTAL
Intervention: G‐CSF with EPO (Group A; n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: G‐CSF and placebo (Group B; n = 30)
Number of subjects: 60
Study: 28414610

Group type: EXPERIMENTAL
Intervention: Nomogram for 90-day mortality
Number of subjects: 22654

Group type: EXPERIMENTAL
Intervention: Multivariable model for 90-day mortality
Number of subjects: 22654
Study: 26380359

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT), 12 sessions
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual outpatient psychiatric care
Number of subjects: 81
Study: 23585303

Group type: EXPERIMENTAL
Intervention: Single dose of biapenem 0.15 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single dose of biapenem 0.3 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single dose of biapenem 0.6 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multiple doses of biapenem 0.3 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 10
Study: 20615931

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg glycine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19820270

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg with omeprazole (40 mg/day for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg without omeprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS XR) 20 mg with omeprazole (40 mg/day for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mixed amphetamine salts extended-release (MAS XR) 20 mg without omeprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MAS XR with omeprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LDX with omeprazole
Number of subjects: 24
Study: 17542205

Group type: EXPERIMENTAL
Intervention: Dentin aged in mineral oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dentin aged in artificial saliva
Number of subjects: 0
Study: 14690849

Group type: EXPERIMENTAL
Intervention: One temporal standard encoded
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two temporal standards encoded
Number of subjects: 0
Study: 11231932

Group type: EXPERIMENTAL
Intervention: Racecadotril (1.5 mg/kg orally 3 times daily)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 9888613

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5, 10, 15, or 20 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lorazepam (2 mg)
Number of subjects: 13
Study: 10350383

Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg od
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg od
Number of subjects: 832

Group type: COMPARATOR
Intervention: Cefuroxime axetil 250 mg bd
Number of subjects: 832
Study: 2620999

Group type: EXPERIMENTAL
Intervention: Verbal bogus‐pipeline protocol (VBP)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Printed cartoon bogus‐pipeline (CBP)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Questionnaire‐only control (QOC)
Number of subjects: 152
Study: 835924

Group type: COMPARATOR
Intervention: Guar gum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pectin (10 g added to marmalade)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Guar and pectin combined
Number of subjects: 12
Study: 31895459

Group type: EXPERIMENTAL
Intervention: New cardiovascular drugs (lipid-modifying, antithrombotic, anti-inflammatory, and antidiabetic drugs)
Number of subjects: 8569

Group type: EXPERIMENTAL
Intervention: New cardiovascular drugs
Number of subjects: 8569
Study: 28368956

Group type: EXPERIMENTAL
Intervention: Low volume plyometric group (LPG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High volume plyometric group (HPG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Leg stiffness
Number of subjects: 36
Study: 29141082

Group type: EXPERIMENTAL
Intervention: Instructions on how best to take photographs using a smartphone (intervention group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No instructions on how to take photographs (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall photograph-based diagnosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-quality photographs subgroup
Number of subjects: 40
Study: 25773480

Group type: EXPERIMENTAL
Intervention: Oral morphine at doses of 0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg
Number of subjects: 40
Study: 24245597

Group type: EXPERIMENTAL
Intervention: Two group-based sessions focused on HIV risk and prevention knowledge and condom skills
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single-session HIV review
Number of subjects: 200
Study: 21118280

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg and 90 mg
Number of subjects: 591
Study: 18810712

Group type: EXPERIMENTAL
Intervention: Oral DHEA (9 subjects)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (6 subjects)
Number of subjects: 15
Study: 17302022

Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock wave treatment (ESWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study: 15577002

Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study: 11208687

Group type: EXPERIMENTAL
Intervention: 24-hour sodium deprivation (decreasing Na)
Number of subjects: 47
Study: 9237964

Group type: EXPERIMENTAL
Intervention: 10 g/d olestra
Number of subjects: 67

Group type: COMPARATOR
Intervention: 10 g/d triglyceride
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 0, 8, 20 or 32 g olestra in potato chips
Number of subjects: 67
Study: 8257487

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg) plus Minocycline (100 mg daily)
Number of subjects: 36
Study: 2943838

Group type: EXPERIMENTAL
Intervention: EC/IC bypass surgery
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1377
Study: 31669564

Group type: EXPERIMENTAL
Intervention: 72 Gy in 36 fractions
Number of subjects: 144

Group type: COMPARATOR
Intervention: 66 Gy in 33 fractions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 72 Gy in 36 fractions (higher Gleason score 8-10)
Number of subjects: 144

Group type: COMPARATOR
Intervention: 66 Gy in 33 fractions (higher Gleason score 8-10)
Number of subjects: 144
Study: 29575547

Group type: COMPARATOR
Intervention: Xenograft (deproteinized bovine bone)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Graftless tenting technique
Number of subjects: 17
Study: 27245384

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain interference
Number of subjects: 0
Study: 24528179

Group type: EXPERIMENTAL
Intervention: 1 year of maintenance with tretinoin, mercaptopurine and methotrexate
Number of subjects: 105

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 105
Study: 22340928

Group type: EXPERIMENTAL
Intervention: Dexamethasone ointment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 19885779

Group type: EXPERIMENTAL
Intervention: Handheld vibration (2.2 mm, 15 Hz, 20 s) using a 2.55 kg Mini‐VibraFlex dumbbell
Number of subjects: 35

Group type: COMPARATOR
Intervention: Still dumbbell (0 mm, 0 Hz, 20 s)
Number of subjects: 35
Study: 17186128

Group type: EXPERIMENTAL
Intervention: Eight-session intervention arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15365537

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 349

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg once daily for 10 days
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 349
Study: 11265938

Group type: EXPERIMENTAL
Intervention: Computerized diabetes monitoring system (DMS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control period (no DMS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DMS acceptance
Number of subjects: 19
Study: 9533608

Group type: EXPERIMENTAL
Intervention: Hardness meter measurement by Observer 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hardness meter measurement by Observer 2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hardness meter measurement at standardized point
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hardness meter measurement between observers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hardness meter measurement at 3 anatomical locations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hardness meter measurement at 3 different speeds
Number of subjects: 20
Study: 7798371

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard antiemetic medication regimen
Number of subjects: 20
Study: 2904696

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (vitamin E)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Simpson-Angus Scale for Extrapyramidal Side Effects
Number of subjects: 15
Study: 6125345

Group type: EXPERIMENTAL
Intervention: 400 mg chlormezanone
Number of subjects: 55

Group type: COMPARATOR
Intervention: 20 mg temazepam
Number of subjects: 55
Study: 31475608

Group type: EXPERIMENTAL
Intervention: High-fidelity simulator (HFS group, n=36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low-fidelity simulator (LFS group, n=35)
Number of subjects: 71
Study: 29246277

Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation (6 g·d‐1 for 28 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study: 26386159

Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant treatment
Number of subjects: 479
Study: 24835860

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol and 600 mg ibuprofen administered one hour before the procedure
Number of subjects: 200

Group type: COMPARATOR
Intervention: No medication administered
Number of subjects: 200
Study: 23055505

Group type: EXPERIMENTAL
Intervention: Central stimulus moving at fast speed in the direction opposite to the surround
Number of subjects: 0

Group type: COMPARATOR
Intervention: Central stimulus moving in the same direction as the surround at a speed such that it appeared stationary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early visual areas (V1, V2, V3, and V3A)
Number of subjects: 0
Study: 19641359

Group type: EXPERIMENTAL
Intervention: Naftopidil (50 mg/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 95
Study: 17123473

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 1914

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 1914
Study: 15198449

Group type: COMPARATOR
Intervention: Cortical relay time (CRT) in control subjects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cortical relay time (CRT) in patients with MS
Number of subjects: 28
Study: 12503232

Group type: EXPERIMENTAL
Intervention: Integrated nutrition program
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (comparison children)
Number of subjects: 238
Study: 9832296

Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical diclofenac gel (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical piroxicam gel (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 8017592

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2670419

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonanoic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioengineering methods (TEWL and electrical conductance)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioengineering methods (blood flow and skin thickness)
Number of subjects: 20
Study: 792844

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of antilymphocyte globulin (ALG) and thoracic duct drainage (TDD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thoracic duct drainage (TDD)
Number of subjects: 20
Study: 30181363

Group type: EXPERIMENTAL
Intervention: Blind tracheal suctioning plus cleaning maneuver every 8 hours (treatment group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard suctioning (control group)
Number of subjects: 39
Study: 28011389

Group type: EXPERIMENTAL
Intervention: One injection of long‐acting naltrexone in prison, followed by 6 monthly injections post‐release at a community opioid treatment program
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: One injection of long‐acting naltrexone in prison followed by 6 monthly injections post‐release at the patient's place of residence utilizing mobile medical treatment
Number of subjects: 240
Study: 25992914

Group type: EXPERIMENTAL
Intervention: Triple therapy: MTX+sulfasalazine (SSZ)+hydroxychloroquine (HCQ)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor (anti-TNF) therapy: MTX+infliximab
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Group B (anti-TNF therapy)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Group A (triple therapy)
Number of subjects: 487
Study: 23234418

Group type: EXPERIMENTAL
Intervention: Whey proteins only (OWT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whey proteins with glucose (OWGT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose only (OGTT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Arginine (AST)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucagon (GST)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous glucose (IVGTT)
Number of subjects: 8
Study: 21792622

Group type: EXPERIMENTAL
Intervention: Upper‐limb robotic therapy
Number of subjects: 24
Study: 19458107

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg with soy extract (Genistein Soy Complex 1000 mg, twice daily for 14 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Losartan 50 mg without soy extract
Number of subjects: 18
Study: 17449466

Group type: EXPERIMENTAL
Intervention: Increased physical activity (PA) measured by accelerometers over 8 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reduced sedentary behavior (TV viewing) assessed by self-report
Number of subjects: 30
Study: 15459410

Group type: COMPARATOR
Intervention: Erythromycin (4 times daily for 10 days)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Ceftriaxone (single dose)
Number of subjects: 673
Study: 11403509

Group type: EXPERIMENTAL
Intervention: Colesevelam 2.3 g at dinner
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lovastatin 10 mg at dinner
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination of colesevelam and lovastatin dosed together
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination of colesevelam and lovastatin dosed apart
Number of subjects: 135

Group type: COMPARATOR
Intervention: Colesevelam alone
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lovastatin alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination treatments
Number of subjects: 135
Study: 9714974

Group type: EXPERIMENTAL
Intervention: Imiquimod cream (2%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7529391

Group type: EXPERIMENTAL
Intervention: 6% Hetastarch (Hespan)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Standard procedures for leukocyte collection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Minor modification of standard techniques
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8 ml of Hespan to 16 ml of blood
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Donor cells, anti‐granulocyte antibody labelling or HIG
Number of subjects: 16
Study: 2970744

Group type: EXPERIMENTAL
Intervention: Reaferon (1 X 10(6) I. U.) administered orally, twice a week for two months.
Number of subjects: 2178

Group type: COMPARATOR
Intervention: Placebo (diluent alone) administered twice a week for two months.
Number of subjects: 2178
Study: 31823620

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 29037471

Group type: EXPERIMENTAL
Intervention: Escalating delayed cash incentive (intervention)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 188
Study: 26304911

Group type: EXPERIMENTAL
Intervention: Cetuximab with docetaxel and cisplatin (CTP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Docetaxel and cisplatin (TP)
Number of subjects: 92
Study: 23277268

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 21503782

Group type: EXPERIMENTAL
Intervention: Xeomin® (12 units)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dysport® (36 units)
Number of subjects: 22
Study: 18006539

Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor (TNF) therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Berlin MRI spine score >/=11
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Disease duration <10 years
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CRP >/=40 mg/litre
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Two or three predictors present
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Disease duration >20 years, normal CRP, no active inflammatory lesion in the spine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MRI score of SI joints
Number of subjects: 46